A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
about
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?Antiangiogenic mechanisms and factors in breast cancer treatmentTargeted Therapies in Triple-Negative Breast CancerPopulation pharmacokinetics of bevacizumab in cancer patients with external validationA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyTargeted anti-vascular therapies for ovarian cancer: current evidenceTargeting the tumor vasculature to enhance T cell activityBevacizumab treatment for advanced breast cancerStroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesisTowards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancerFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentTargeting the vascular endothelial growth factor pathway in the treatment of human malignancy.More sound cancer therapy biomarker development with active noise control.Normalization of the vasculature for treatment of cancer and other diseases.Metabolic tumor profiling with pH, oxygen, and glucose chemosensors on a quantum dot scaffold.Host endothelial S1PR1 regulation of vascular permeability modulates tumor growthClinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Emerging drugs for diabetic retinopathy.Phase II open-label study of sunitinib in patients with advanced breast cancer.Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review studyBevacizumab and breast cancer: current therapeutic progress and future perspectivesGU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer.Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.Immunological Approaches in the Treatment of Metastasized Breast CancerAntibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies.Present and future evolution of advanced breast cancer therapy.Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy.Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancerThe vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoAntiangiogenic therapy for breast cancerBevacizumab in the treatment of patients with advanced breast cancer: where have we landed?Bevacizumab in metastatic breast cancer: when may it be used?Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody.Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer.Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
P2860
Q24794969-3E471DED-21A3-48D0-9455-6D6DA1E8DD01Q26751226-2F4E3946-AE9D-4952-A447-48E0AE19D64DQ26777736-E7AA4BEF-DB46-4F30-8DDE-C1AC6DDF686AQ26779580-40738E78-3D02-4468-8E80-2ED5A62765B4Q26824462-3BAD0872-FD76-4DFA-AD63-1E829A8BDEB7Q26830287-A1A4CAD3-F28C-471D-8EA1-8106BB322CFDQ27026329-63C827FF-B006-4D29-A4CC-725084469EB0Q27027498-722AC3D9-70FC-4C2D-8ADA-3EE9E9DE6276Q28260997-D1F9B560-7F20-44DB-A56E-34130922B08AQ28291499-46C8EE64-D6D7-4ACA-894F-A66286BAD8E2Q28533949-E9BE67B9-03DE-4B60-A891-70E1101F1CD8Q30358961-95CD4890-52AF-418A-B542-DA8B40F52051Q30442454-FADB75EC-B925-4214-B4C7-6EFF056EF580Q30471456-998C6540-CA29-43D2-87AE-B9B33C1CDAAAQ30573562-F317DDFD-0BE3-4CA9-A425-406EC7BBFF66Q30582575-DEE0D8C3-7044-4318-9725-7F145034DD4DQ31157714-D94F5059-95CB-4CFD-BB72-4386AC24AB84Q33388498-A8918210-2C33-48FC-B16C-3301F78C5002Q33403848-FE859781-87BB-4CF3-934D-038DFA13A3DFQ33506194-20F1212D-07B3-4BF5-939F-142AC1096F89Q33640753-50141024-6997-42B2-BC95-444E36FBB5A6Q33645920-BFB27C3D-2EEB-490C-AA46-C8791EAD53E4Q33794403-A6177AB0-B3A4-4225-942D-C66F9603E498Q33807542-1DEB837B-4165-4490-9A9A-35E3AFED3D9EQ34028780-45628442-0F41-49BD-9CD8-D85300C3C440Q34140043-48E6F5FA-916F-4E2F-AFAA-D58172C1E8CBQ34140167-A3CE6D90-7CF1-4451-97AA-1556A1DF4B17Q34274925-453F8E49-38F1-4697-BC76-D2AD11AA6833Q34523039-C124DD44-87F2-4537-9262-9513DF5C863CQ34544166-E4F71227-76D3-4A54-9EF0-5DA5909701DAQ34768492-0D21E32D-97CD-4E1B-989E-5E3EDBD827EAQ34787422-EF912AF9-7FDF-4764-BE67-A0F49F508476Q34989039-7A4B96D2-0B92-463D-ABE8-979548377385Q35076287-CF600B1C-F759-488D-A48E-EE09DD683864Q35076351-F7F6A8FC-6B23-4543-9B21-A5805AE1C899Q35092548-6CDA703E-F3A1-4706-9F84-0D6A15D2F44CQ35346619-F3B53533-77A5-494A-A5F3-B69AD71010F5Q35584239-3AC534D2-B241-4FB5-9A01-E214CC37EF85Q35607779-E0CCD443-A8B0-4EEB-9052-12B48CA5D419Q35626845-B1C194E0-21F7-42B3-80E4-E597B9D22DD2
P2860
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@ast
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@en
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@nl
type
label
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@ast
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@en
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@nl
prefLabel
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@ast
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@en
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@nl
P2093
P921
P3181
P1433
P1476
A phase I/II dose-escalation t ...... eated metastatic breast cancer
@en
P2093
Amy Vassel
George W Sledge
James D Reimann
Kathy D Miller
Latrice Haney
Melody A Cobleigh
Virginia K Langmuir
William F Novotny
P304
P3181
P356
10.1053/J.SEMINONCOL.2003.08.013
P407
P433
5 Suppl 16
P577
2003-10-01T00:00:00Z